Trial · NCT03194646
Results by group112
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 112
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage Change in Bone Mineral Density (BMD) of Lumbar Spine | Vilaprisan 2 mg A1 (3/1 Regimen) | -1.56 | Standard Deviation 2.72 | Percentage change | |
| Percentage Change in Bone Mineral Density (BMD) of Lumbar Spine | Vilaprisan 2 mg A2 (6/2 Regimen) | -2.04 | Standard Deviation 2.50 | Percentage change | |
| Percentage Change in Bone Mineral Density (BMD) of Lumbar Spine | Vilaprisan 2 mg A3 (3/2 Regimen) | -1.51 | Standard Deviation 2.28 | Percentage change | |
| Percentage Change in Bone Mineral Density (BMD) of Lumbar Spine | B (Standard of Care) | 0.29 | Standard Deviation 2.36 | Percentage change | |
| Number of Bleeding Days | Vilaprisan 2 mg A1 (3/1 Regimen) | 1.57 | Standard Deviation 1.99 | Days | |
| Number of Bleeding Days | Vilaprisan 2 mg A2 (6/2 Regimen) | 1.74 | Standard Deviation 2.52 | Days | |
| Number of Bleeding Days | Vilaprisan 2 mg A3 (3/2 Regimen) | 1.81 | Standard Deviation 1.24 | Days | |
| Number of Bleeding Days | B (Standard of Care) | 4.72 | Standard Deviation 4.60 | Days | |
| Number of Participants With Endometrial Histology Findings by Endometrial Biopsy Main Results (Majority Read, Main Diagnosis) | Vilaprisan 2 mg A1 (3/1 Regimen) | Adequate endometrial tissue | 346 | Participants | |
| Number of Participants With Endometrial Histology Findings by Endometrial Biopsy Main Results (Majority Read, Main Diagnosis) | Vilaprisan 2 mg A2 (6/2 Regimen) | Adequate endometrial tissue | 346 | Participants | |
| Number of Participants With Endometrial Histology Findings by Endometrial Biopsy Main Results (Majority Read, Main Diagnosis) | Vilaprisan 2 mg A3 (3/2 Regimen) | Adequate endometrial tissue | 175 | Participants | |
| Number of Participants With Endometrial Histology Findings by Endometrial Biopsy Main Results (Majority Read, Main Diagnosis) | B (Standard of Care) | Adequate endometrial tissue | 359 | Participants | |
| Number of Participants With Endometrial Histology Findings by Endometrial Biopsy Main Results (Majority Read, Main Diagnosis) | Vilaprisan 2 mg A1 (3/1 Regimen) | Benign Endometrium | 346 | Participants | |
| Number of Participants With Endometrial Histology Findings by Endometrial Biopsy Main Results (Majority Read, Main Diagnosis) | Vilaprisan 2 mg A2 (6/2 Regimen) | Benign Endometrium | 346 | Participants | |
| Number of Participants With Endometrial Histology Findings by Endometrial Biopsy Main Results (Majority Read, Main Diagnosis) | Vilaprisan 2 mg A3 (3/2 Regimen) | Benign Endometrium | 175 | Participants | |
| Number of Participants With Endometrial Histology Findings by Endometrial Biopsy Main Results (Majority Read, Main Diagnosis) | B (Standard of Care) | Benign Endometrium | 359 | Participants | |
| Number of Participants With Endometrial Histology Findings by Endometrial Biopsy Main Results (Majority Read, Main Diagnosis) | Vilaprisan 2 mg A1 (3/1 Regimen) | Hyperplasia WHO 2014, no atypia | 0 | Participants | |
| Number of Participants With Endometrial Histology Findings by Endometrial Biopsy Main Results (Majority Read, Main Diagnosis) | Vilaprisan 2 mg A2 (6/2 Regimen) | Hyperplasia WHO 2014, no atypia | 0 | Participants | |
| Number of Participants With Endometrial Histology Findings by Endometrial Biopsy Main Results (Majority Read, Main Diagnosis) | Vilaprisan 2 mg A3 (3/2 Regimen) | Hyperplasia WHO 2014, no atypia | 0 | Participants | |
| Number of Participants With Endometrial Histology Findings by Endometrial Biopsy Main Results (Majority Read, Main Diagnosis) | B (Standard of Care) | Hyperplasia WHO 2014, no atypia | 0 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03194646/results